CHESTER, N.J., March 14, 2018 /PRNewswire/ -- Hillstream BioPharma Inc., a development-stage biopharmaceutical company dedicated to developing cancer therapeutics with greater safety and efficacy by encapsulating them in proprietary polymeric nanoparticles comprised of FDA-recognized inactive ingredients, today announced that it will present at the B. Riley & Co. 2018 China Healthcare Investing & Partnering Symposium, taking place March 15 – 17 in Hangzhou, China.
Randy Milby, CEO of Hillstream, will highlight the company's pipeline of novel formulations of bortezomib and oxaliplatin, and will provide an overview of the company's anticipated financial and clinical milestones. In addition, he will present Hillstream's plans to take advantage of the FDA's 505(b)(2) regulatory pathway, expediting the development process and bringing novel formulations to market to help patients with unmet medical needs.
Date: March 16, 2018
Time: 1:00 PM China Standard Time (UTC+8)
Location: InterContinental Hangzhou (Room A)
An audio webcast will be accessible at the following link. An archive of the audio will remain available following the presentation: http://wsw.com/webcast/brileyco20/hsbi/
About Hillstream BioPharma Inc.
Hillstream BioPharma is a development-stage company advancing improved therapies for patients with cancer. Hillstream's competitive advantage is to enhance the safety and efficacy of FDA-approved oncology therapies by encapsulating them in proprietary polymeric nanoparticles comprised of FDA-recognized inactive ingredients. Encapsulation ensures delivery within the tumor cells and prevents free drug levels in circulation that can cause toxicity. The slow and sustained release of the therapy may also reduce the frequency of dosing while maintaining its efficacy. The novel formulation allows Hillstream to build a strong patent estate and seek FDA Orphan Drug Designation in specific indications. Hillstream's proprietary formulations of bortezomib and oxaliplatin are currently in preclinical development for cancers with significant unmet need. By taking advantage of the FDA's 505(b)(2) regulatory pathway, the Company could expedite the development process and bring these novel formulations to market to offer patients hope.
Janine McCargo (Media)
SOURCE Hillstream BioPharma Inc.